Chemotherapy Clinical Trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 902 clinical trials
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.

erbb2
HER2
her1
primary tumor
core needle biopsy
  • 0 views
  • 19 Feb, 2024
  • 1 location
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

resectable pancreatic ductal adenocarcinoma
paclitaxel
serum total bilirubin level
gemcitabine
absolute neutrophil count
  • 0 views
  • 19 Feb, 2024
  • 30 locations
A Trial of Neoadjuvant mXELOXIRI Versus CRT in the EMVI Positive LARC

The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT).

renal function
platelet count
cancer
adenocarcinoma
chemoradiotherapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Immunotherapy may also contribute to the efficacy of systemic treatment by maintaining initial responses to chemotherapy. A double-blind, placebo-controlled phase 3 trial indicates that the addition of atezolizumab to standard chemotherapy significantly improves overall survival and progression-free survival compared with chemotherapy alone in treatment-nave patients with ED-SCLC who are in …

lung cancer
non-small cell lung cancer
liver metastasis
tuberculosis
neuroendocrine tumor
  • 0 views
  • 19 Feb, 2024
  • 1 location
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

lung cancer
non-small cell lung cancer
hepatitis
hiv test
cancer
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Fuzheng Yiliu-1010

Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population of Fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and …

oxaliplatin
renal function
folfox regimen
metastasis
adenocarcinoma of the colon
  • 0 views
  • 19 Feb, 2024
  • 1 location
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Previous case studies showed that Bortezomib, a proteasome inhibitor, may achieve remission in refractory ALL, 80% remission in B-ALL with combination of chemotherapy and bortezomib. Thus adding bortezomib, may improve the remission rate, thus bridging to allogeneic stem cell transplant. Adding bortezomid in the relapsed chemotherapy protocol may increase the …

bortezomib injection
leukemia
flow cytometry
proteasome inhibitor
leukemic cells
  • 0 views
  • 19 Feb, 2024
  • 1 location
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma

This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study.

blood transfusion
renal function
nivolumab
screening procedures
malignant glioma
  • 0 views
  • 19 Feb, 2024
  • 1 location